Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

Recent studies suggest CD133, a surface protein widely used for isolation of colon cancer stem cells, to be associated with tumor angiogenesis and recurrence. We hypothesized that gene expression levels and germline variations in CD133 will predict clinical outcome in patients with mCRC, treated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pohl, Alexandra, El-Khoueiry, Anthony, Yang, Dongyun, Zhang, Wu, Lurje, Georg, Ning, Yan, Winder, Thomas, Hu-Lieskoven, Siwen, Iqbal, Sima, Danenberg, Kathleen D., Kahn, Michael, Teo, Jia-Ling, Shriki, Jabi, Stebbing, Justin, Lenz, Heinz-Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326190/
https://www.ncbi.nlm.nih.gov/pubmed/22231565
http://dx.doi.org/10.1038/tpj.2011.61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326190/
https://www.ncbi.nlm.nih.gov/pubmed/22231565
http://dx.doi.org/10.1038/tpj.2011.61

Ejemplares similares